Intelligence · Patents
Patents expiring in 2037
Annual patent cliff calendar for 2037 — US pharmaceutical patents by expiration date.
- Patents
- 1,615
Quick answer
1,615 indexed pharmaceutical patents have expiration dates in 2037. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 9540427
Peptide-based stat inhibitor
granted -
US 9539337
Compositions comprising two different populations of polymer-active agent conjugates
granted -
US 9540642
Compositions and methods for controlling arthropod parasite and pest infestations
granted -
US 9540395
Histone deacetylase inhibitors
granted -
US 9540334
2,4-pyrimidinediamine compounds and their uses
granted -
US 9539340
Bladder cancer specific ligand peptides
granted -
US 9540337
Gamma-glutamyl transpeptidase inhibitors and methods of use
granted -
US 9540641
Cancer treatment
granted -
US 9540643
Organic compositions to treat HSF1-related diseases
granted -
US 9540440
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
granted -
US 9540380
Imidazotriazinone compounds
granted -
US 9539220
Methods for treating suicidal ideation
granted -
US 9539341
Methods and compositions for targeting adipose cells in mammals
granted -
US 9540330
Oligomer-containing hydantoin compounds
granted -
US 9539228
Composition containing lysine as a nutritional supplement or treatment in the case of herpes
granted -
US 9539234
Treatment of circadian rhythm disorders
granted -
US 9539330
Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
granted -
US 9539342
Auristatin tyramine phosphate salts and auristatin aminoquinoline derivatives and prodrugs thereof
granted -
US 9540415
Inhibitors of the farnesoid X receptor and uses in medicine
granted -
US 9541545
Fluorescent neutralization and adherence inhibition assays
granted -
US 9540471
Nitric oxide-releasing diazeniumdiolated polyvinylpyrrolidone-based polymers, and compositions, medical devices, and uses thereof
granted -
US 9540449
Anti-PCSK9 antibodies with pH-dependent binding characteristics
granted -
US 9539301
Melanotropin ligands for skin care
granted -
US 9539231
Method for treating triple-negative breast cancer using AMPI-109
granted -
US 9539207
Method for delivering pramlintide into a lumen of the intestinal tract using a swallowable drug delivery
granted -
US 9539256
Modulators of exchange proteins directly activated by cAMP (EPACS)
granted -
US 9539283
Citrate-rich calcium-magnesium supplement and uses thereof
granted -
US 9539300
Modulating disease through genetic engineering of plants
granted -
US 9539321
HMGB1-derived peptides enhance immune response to antigens
granted -
US 9545452
Biomineral and metal binding liposomes, their synthesis, and methods of use thereof
granted -
US 9545370
Bioactive compositions and methods for their preparation and use
granted -
US 9546193
Compositions and methods for 18F-fluorodeoxyglycosylamines
granted -
US 9545451
Anti-PRLR antibodies and methods for killing PRLR-expressing cells
granted -
US 9545443
Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
granted -
US 9546370
QSOX1 as an anti-neoplastic drug target
granted -
US 9545461
Anti-microbial peptides and methods of use thereof
granted -
US 9545431
Isolated recombinant cDNA
granted -
US 9546164
Substituted benzamides and methods of use thereof
granted -
US 9546188
Complexes of germanium with amino acids and carboxylic acids and method for preparing same
granted -
US 9546176
Small molecule bicyclic and tricyclic CFTR correctors
granted -
US 9545422
Methods of inducing photosensitivity by targeting channelrhodopsin-2 and halorhodopsin to subcellular regions of retinal ganglion cells
granted -
US 9546218
Anti-Tie2 antibodies and uses thereof
granted -
US 9546368
Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1 (MALAT-1) expression
granted -
US 9546151
VMAT inhibitory compounds
granted -
US 9545441
Treatment of diabetes
granted -
US 9545442
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
granted -
US 9549943
A3 adenosine receptor ligands for use in treatment of a sexual dysfunction
granted -
US 9550078
EDAR ligand derived peptides and use thereof
granted
Frequently asked questions
How many pharma patents expire in 2037?
1,615 published patents in our USPTO index have expiration dates falling in calendar year 2037.